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Abstract: Purpose: To survey risk-reducing hysterectomy and bilateral salpingo-oophorectomy
(BSO) practice and advice regarding hormone replacement therapy (HRT) in women with Lynch
syndrome. Methods: We conducted a survey in 31 contributing centers from the Prospective Lynch
Syndrome Database (PLSD), which incorporates 18 countries worldwide. The survey covered local
policies for risk-reducing hysterectomy and BSO in Lynch syndrome, the timing when these measures
are offered, the involvement of stakeholders and advice regarding HRT. Results: Risk-reducing
hysterectomy and BSO are offered to path_MLH1 and path_MSH2 carriers in 20/21 (95%) contributing
centers, to path_MSH6 carriers in 19/21 (91%) and to path_PMS2 carriers in 14/21 (67%). Regarding the
involvement of stakeholders, there is global agreement (~90%) that risk-reducing surgery should
be offered to women, and that this discussion may involve gynecologists, genetic counselors and/or
medical geneticists. Prescription of estrogen-only HRT is offered by 15/21 (71%) centers to women of
variable age range (35–55 years). Conclusions: Most centers offer risk-reducing gynecological surgery
to carriers of path_MLH1, path_MSH2 and path_MSH6 variants but less so for path_PMS2 carriers.
There is wide variation in how, when and to whom this is offered. The Manchester International
Consensus Group developed recommendations to harmonize clinical practice across centers, but there
is a clear need for more research.
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1. Background
Lynch syndrome is one of the most common hereditary cancer syndromes, affecting an estimated
1 in 300 individuals, based on the prevalence of underlying genetic abnormalities in the general
population. It is caused by pathogenic variants affecting one of the DNA mismatch repair (MMR)
genes (path_MMR): path_MLH1, path_MSH2, path_MSH6 and path_PMS2, each of which results in
different risks for cancer, particularly colorectal, endometrial and ovarian cancer [1].
Women with Lynch syndrome (excepting path_PMS2) have a lifetime risk of up to 50% of
developing colorectal and endometrial cancer and a lower risk (up to 17%) of developing ovarian
cancer [2]. Risk estimates for age-related gynecological cancer in Lynch syndrome vary by gene,
as described by the Prospective Lynch Syndrome Database (PLSD). PLSD reported a cumulative
incidence of endometrial and ovarian cancer at 75 years of 37% and 11% for path_MLH1 carriers, 49%
and 17% for path_MHS2 carriers and 41% and 11% for path_MSH6 carriers, respectively [2]. Notably,
female path_MSH6 carriers are at highest risk of endometrial cancer compared with cancer in other
organs [2–4].
Whilst colonoscopy surveillance has been associated with improved survival by early detection
of colorectal lesions compared with no surveillance [5], there is limited evidence that gynecological
cancer surveillance offers a survival benefit due to a lack of high-quality trial data [6]. Nevertheless,
a 98% 10-year survival from endometrial cancer has been reported by the PLSD in women who are
known path_MMR carriers, suggesting that surveillance and/or increased awareness of the red flag
symptoms of gynecological cancers may enable detection at early stages when cure is more likely [4].
In contrast, risk-reducing hysterectomy and BSO have been shown to prevent gynecological cancer
in women with Lynch syndrome [7]. The Manchester International Consensus Group recommendations
for the management of gynecological cancers in Lynch syndrome suggested that risk-reducing total
hysterectomy and BSO should be offered no earlier than 35–40 years of age, following completion of
childbearing, to path_MLH1, path_MSH2 and path_MSH6 carriers. However, the group concluded
that there was insufficient evidence to offer risk-reducing surgery to path_PMS2 carriers, whose risk
of gynecological cancers is appreciably lower [6,8]. The prescription of estrogen-only replacement
therapy (HRT) until at least natural menopause (~51 years) was strongly recommended for women
who undergo risk-reducing surgery [6].
In this report, we describe the current practice for hysterectomy and BSO reported by each PLSD
contributing center. We also explore reasons for divergence in the participating centers at the time of
the survey.
2. Methods
All contributing centers were asked to complete a structured survey of current practice of
risk-reducing gynecological surgery by April 2019 (Table 1). Data were collected via a structured
questionnaire (with areas for qualitative data collection).
The survey covered questions regarding the current practice for path_MLH1, path_MSH2,
path_MSH6 and path_PMS2 carriers, including risk-reducing hysterectomy and BSO and the timing
of surgery. We asked each center about the involvement of the patient and healthcare professional
stakeholders in initiating discussions about risk-reducing gynecological surgery, whether surgery was
actively recommended and if so, for whom.
Data were exported to an excel file, and descriptive statistics were used to catalogue the findings.
Local guidelines for gynecological surveillance and the modalities used are shown in Supplementary
Table 1.
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Table 1. Survey covering questions regarding the current practice with respect to prophylactic
hysterectomy and/or bilateral salpingo-oophorectomy (BSO) in path_MMR carriers.
Current
Practice
Path_MLH1
Carrier
Path_MSH2
Carrier
Path_MSH6
Carrier
Path_PMS2
Carrier
Prophylactic
hysterectomy
Available (Y/N)
If so, at which age
If so, only if patient asks *
If so, to be mentioned by counsellor *
If so, to be advocated by counsellor *
Prophylactic
oophorectomy
Available(Y/N)
If so, at which age
If so, only if patient asks **
If so, to be mentioned by counsellor **
If so, to be advocated by counsellor **
If premenopausal oophorectomy,
HRT to which age?
*/** mutually exclusive, answer only one for each gene; */** please specify who the counsellor would be (more than
one if applicable), e.g. gynecologist, medical geneticist, genetic counsellor, GP, other.
3. Results
3.1. Survey Response
We conducted the survey in 31 participating medical centers, from 18 countries. Of the thirty-one
centers, 21 (68%) from 12 countries, including Germany (n = 5), Finland (n = 1), Australia (n = 1), Spain
(n = 1), the United Kingdom (n = 2), Norway (n = 1), The Netherlands (n = 2), Italy (n = 3), Sweden
(n = 1), Israel (n = 2), Switzerland (n = 1) and Argentina (n = 1), completed the survey (Table 2).
Table 2. Currently recommended practice for females with path_MMR variants in the Prospective
Lynch Syndrome Database (PLSD) by country.
Countries Number
of Centers
Path_MLH1 and Path_MSH2
Carriers Path_MSH6 Carriers Path_PMS2 Carriers
Prophylactic
Hysterectomy
Prophylactic
BSO
Prophylactic
Hysterectomy
Prophylactic
BSO
Prophylactic
Hysterectomy
Prophylactic
BSO
Germany 5 5 5 5 5 5 5
Finland 1 1 1 1 1 1 1
Australia 1 1 1 1 1 1 1
Spain 1 1 1 1 1 1 1
UK 2 2 2 2 2 1 1
Norway 1 1 1 1 1 1 1
The Netherlands 2 2 2 2 2 0 0
Italy 3 3 3 3 3 1 1
Sweden 1 1 1 1 1 1 1
Israel 2 2 2 1 1 1 1
Switzerland * 1 0 0 0 0 0 0
Argentina 1 1 1 1 1 1 1
Total 21 20 20 19 19 14 14
*: There is no national guidelines or statements for female Lynch syndrome patients yet; BSO: bilateral
salpingo-oophorectomy.
3.2. Risk-Reducing Hysterectomy and BSO as Measures to Prevent Gynecological Cancer in
Path_MMR Carriers
Risk-reducing hysterectomy and BSO are offered in 20/21 (95%) centers for path_MLH1 and
path_MSH2 carriers. For path_MSH6 carriers, risk-reducing hysterectomy and BSO are offered in
19/21 (91%) centers. Fourteen out of 21 (67%) centers offer risk-reducing hysterectomy and BSO
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for path_PMS2 carriers (Table 2). The most common reported age at which risk-reducing surgery
is currently offered is ≥40 years in path_MMR carriers. Prescription of estrogen-only HRT after
premenopausal oophorectomy is recommended by 15/21 (71%) centers, across a variable age range
(35–55 years).
3.3. Involvement of Stakeholders
3.3.1. Risk-Reducing Hysterectomy
Of the 21 centers, 11 provided information about which stakeholders are involved in initiating
discussions about risk-reducing hysterectomy with Lynch syndrome carriers. Ten (91%) centers stated
that healthcare professionals (mainly gynecologists, genetic counselors and medical geneticists) offer
advice about risk-reducing hysterectomy to women with Lynch syndrome, and 6/9 (67%) centers that
provided further information stated that risk-reducing hysterectomy is actively recommended. Of the
21 centers, only 4 provided information about patient engagement in discussions about risk-reducing
hysterectomy. Of these four centers, one (25%) reported that risk-reducing hysterectomy is only
provided upon request by Lynch syndrome carriers.
3.3.2. BSO
With regards to risk-reducing BSO, 10/21 centers provided information about stakeholder
involvement in these discussions. Nine (90%) centers stated that healthcare professionals
(mainly gynecologists, genetic counselors and medical geneticists) offer advice to Lynch syndrome
carriers about risk-reducing BSO. In 9/10 centers, risk-reducing BSO is advocated by healthcare
professionals, and in 5/9 (56%), it is actively recommended. Of the 21 centers, 6 provided information
about the involvement of patients in discussions about risk-reducing BSO. Three of those centers (50%)
stated that surgery is only provided upon request by Lynch syndrome carriers.
4. Discussion
Here, we provide insight into the current management of gynecological cancer risk in women
with Lynch syndrome across participating PLSD centers. We received data from 21/31 (68%) PLSD
centers, incorporating practices from 12 countries worldwide. There was global agreement (>90%)
for offering both hysterectomy and BSO to path_MLH1, path_MSH2 and path_MSH6 carriers after
the age of 40 years. The reported age at which risk-reducing surgery is offered is later than the
minimum age (35 years) for path_MLH1 and path_MSH2 carriers suggested by the recent expert
consensus statement [6], which was based on the reported rapidly rising risk of gynecological cancers
for path_MSH2 and path_MSH6 carriers from that age onwards [2]. Despite the very low risk for
gynecological cancer in path_PMS2 carriers, risk-reducing hysterectomy and BSO are still offered by
67% of the responding centers. Interestingly, we identified no major differences between the countries,
but there are some discrepancies between centers from the same country (e.g., the UK, The Netherlands
and Israel). Of note, the survey was taken one year ago (April 2019), and some retrospective and
prospective data studies on ovarian and endometrial cancer risk in Lynch syndrome were just being
published [8–10]. This may explain the discrepancies between centers, especially for path_PMS2
carriers, whereby some centers (e.g., The Netherlands) have adapted their practice, but changes have
not been incorporated into national guidelines yet, whilst other centers (e.g., Switzerland) rely on
recommendations from European and US guidelines/statements.
Decisions about risk-reducing surgery reflect discussions between women and healthcare providers
that incorporate a range of issues, including personalized risk calculations, advantages/disadvantages
of risk-reducing surgery, gynecological health, medical co-morbidity, family planning, and women’s
values and preferences. The complexity of these individualized discussions cannot be captured in
a simple survey of this nature. Nevertheless, we sought to understand more about the drivers for
these discussions, whether healthcare professionals are active or passive in providing risk-reducing
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gynecological surgery, and whether this differs by center, country, surgery type (hysterectomy versus
BSO) and affected gene. Most centers offer risk-reducing hysterectomy and/or BSO, but there is a
huge variation between centers as to whether surgery is actively recommended or provided only upon
patient request. This likely reflects inconsistency in national and international guidelines underpinned
by a lack of high-quality published studies. There is a clear unmet clinical need for more research in
this area to guide a consistent approach to risk-reducing gynecological surgery for Lynch syndrome
carriers irrespective of where an individual woman lives and who is involved in her care [11].
The prescription of HRT following premenopausal oophorectomy is recommended in 71% of the
centers from 35 years for a variable duration of up to 55 years of age. The reported ages at which HRT
is offered is not in line with the strong recommendation by the Manchester International Consensus
Group that suggests HRT is offered until at least the age of natural menopause (~51 years) [6]. Some
centers do not prescribe HRT at all; it is notable that the current National Comprehensive Cancer
Network (NCCN) guidelines for risk management for women with Lynch syndrome do not mention
prescription of HRT [12]. However, estrogen protects against colorectal cancer [13–18], which is
particularly relevant for Lynch syndrome carriers, as well as protecting bone and cardiovascular
health [19,20]. Many of the well-publicized harms associated with HRT relate to its prolonged use in
older women and specifically from the progestin component that is not required when the uterus is
removed [21,22].
Risk-reducing hysterectomy and/or BSO has been reported to prevent cancer and/or to improve
survival in women with Lynch syndrome [7]. For women who choose not to undergo risk-reducing
surgery, an understanding of the ‘red flag’ symptoms for these cancers is important to trigger prompt
referral for urgent investigation [23]. A woman’s personal risk should be used to provide individualized
counselling regarding the need for risk-reducing surgery and the optimal timing of this.
5. Conclusions
This study provides a snapshot of the preventive gynecological recommendations provided to
women with Lynch syndrome by 21 centers from 18 countries worldwide. There is a wide variation in
how, when and to whom risk-reducing gynecological surgery is offered. The Manchester International
Consensus Group developed guidance to harmonize the care offered to women with Lynch syndrome
but noted the lack of high-quality research in this area. There is a clear need for further research so
that women with Lynch syndrome can expect and receive consistent, evidence-based care for the
management of their gynecological cancer risk.
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